Viral vectors and delivery strategies for CNS gene therapy

Steven J. Gray, Kenton T. Woodard, R. Jude Samulski

Research output: Contribution to journalReview article

38 Citations (Scopus)

Abstract

This review aims to provide a broad overview of the targets, challenges and potential for gene therapy in the CNS, citing specific examples. There are a broad range of therapeutic targets, with very different requirements for a suitable viral vector. By utilizing different vector tropisms, novel routes of administration and engineered promoter control, transgenes can be targeted to specific therapeutic applications. Viral vectors have proven efficacious in preclinical models for several disease applications, spurring several clinical trials. While the field has pushed the limits of existing adeno-associated virus-based vectors, a next generation of vectors based on rational engineering of viral capsids should expand the application of gene therapy to be more effective in specific therapeutic applications.

Original languageEnglish (US)
Pages (from-to)517-534
Number of pages18
JournalTherapeutic Delivery
Volume1
Issue number4
DOIs
StatePublished - Oct 1 2010

Fingerprint

Genetic Therapy
Dependovirus
Tropism
Capsid
Transgenes
Therapeutics
Clinical Trials

ASJC Scopus subject areas

  • Pharmaceutical Science

Cite this

Viral vectors and delivery strategies for CNS gene therapy. / Gray, Steven J.; Woodard, Kenton T.; Samulski, R. Jude.

In: Therapeutic Delivery, Vol. 1, No. 4, 01.10.2010, p. 517-534.

Research output: Contribution to journalReview article

Gray, Steven J. ; Woodard, Kenton T. ; Samulski, R. Jude. / Viral vectors and delivery strategies for CNS gene therapy. In: Therapeutic Delivery. 2010 ; Vol. 1, No. 4. pp. 517-534.
@article{2816efa83bb74077bb4e474a1042ea94,
title = "Viral vectors and delivery strategies for CNS gene therapy",
abstract = "This review aims to provide a broad overview of the targets, challenges and potential for gene therapy in the CNS, citing specific examples. There are a broad range of therapeutic targets, with very different requirements for a suitable viral vector. By utilizing different vector tropisms, novel routes of administration and engineered promoter control, transgenes can be targeted to specific therapeutic applications. Viral vectors have proven efficacious in preclinical models for several disease applications, spurring several clinical trials. While the field has pushed the limits of existing adeno-associated virus-based vectors, a next generation of vectors based on rational engineering of viral capsids should expand the application of gene therapy to be more effective in specific therapeutic applications.",
author = "Gray, {Steven J.} and Woodard, {Kenton T.} and Samulski, {R. Jude}",
year = "2010",
month = "10",
day = "1",
doi = "10.4155/tde.10.50",
language = "English (US)",
volume = "1",
pages = "517--534",
journal = "Therapeutic Delivery",
issn = "2041-5990",
publisher = "Future Science",
number = "4",

}

TY - JOUR

T1 - Viral vectors and delivery strategies for CNS gene therapy

AU - Gray, Steven J.

AU - Woodard, Kenton T.

AU - Samulski, R. Jude

PY - 2010/10/1

Y1 - 2010/10/1

N2 - This review aims to provide a broad overview of the targets, challenges and potential for gene therapy in the CNS, citing specific examples. There are a broad range of therapeutic targets, with very different requirements for a suitable viral vector. By utilizing different vector tropisms, novel routes of administration and engineered promoter control, transgenes can be targeted to specific therapeutic applications. Viral vectors have proven efficacious in preclinical models for several disease applications, spurring several clinical trials. While the field has pushed the limits of existing adeno-associated virus-based vectors, a next generation of vectors based on rational engineering of viral capsids should expand the application of gene therapy to be more effective in specific therapeutic applications.

AB - This review aims to provide a broad overview of the targets, challenges and potential for gene therapy in the CNS, citing specific examples. There are a broad range of therapeutic targets, with very different requirements for a suitable viral vector. By utilizing different vector tropisms, novel routes of administration and engineered promoter control, transgenes can be targeted to specific therapeutic applications. Viral vectors have proven efficacious in preclinical models for several disease applications, spurring several clinical trials. While the field has pushed the limits of existing adeno-associated virus-based vectors, a next generation of vectors based on rational engineering of viral capsids should expand the application of gene therapy to be more effective in specific therapeutic applications.

UR - http://www.scopus.com/inward/record.url?scp=79954471529&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79954471529&partnerID=8YFLogxK

U2 - 10.4155/tde.10.50

DO - 10.4155/tde.10.50

M3 - Review article

C2 - 22833965

AN - SCOPUS:79954471529

VL - 1

SP - 517

EP - 534

JO - Therapeutic Delivery

JF - Therapeutic Delivery

SN - 2041-5990

IS - 4

ER -